PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS
The Pharma Data
MAY 4, 2021
down 21%, driven by a negative impact from the COVID-19 pandemic resulting in a decline in patient visits to doctors for preventative health purposes, as well as the loss of patent protection in the U.S. Lorbrena is now indicated for adults with metastatic NSCLC whose tumors are ALK-positive as detected by an FDA-approved test.
40 
Let's personalize your content